Weekly injection, semaglutide
Wegovy weight loss injection
Wegovy is a weekly semaglutide injection and the most studied GLP-1 for weight loss. Pen format and pack quantity depend on the prescribed dose and presentation.
Prices to be confirmed
Starter dose, weeks 1 to 4
Explore WegovyThe planned service requires a clinical assessment before any treatment can be supplied. The secure assessment is not connected in this preview. Read how assessment works or prepare a discussion checklist. Provider details, prices and delivery arrangements must be confirmed before launch.
- UK prescriber review
- Dispensing arrangements to be confirmed
- Delivery arrangements to be confirmed
In short: Wegovy (semaglutide) is a once-weekly injection in doses from 0.25 mg to 7.2 mg. Average weight loss was 14.9% at 68 weeks on 2.4 mg in the STEP 1 trial. Aero’s prices are not yet confirmed.
How Wegovy works
GLP-1 is the hormone your gut releases after eating to tell your brain you are full. Semaglutide mimics GLP-1 and lasts a whole week per injection.
Appetite drops, portions shrink, and the background hum of cravings fades. In the SELECT trial, semaglutide also reduced the risk of major cardiovascular events by 20% in people with existing heart disease.
Prefer not to inject? The Wegovy pill delivers the same medicine as a daily tablet.
Wegovy doses and prices
At 7.2 mg, the prescribed presentation may use one single-dose 7.2 mg pen per week or three consecutive 2.4 mg injections. Confirm the supplied device and pack quantity with your pharmacy. Wegovy UK product information, sections 2 and 4.2.
Everyone starts at 0.25 mg. Steps last at least 4 weeks, and you move up only when you and your prescriber agree.
| Dose | Price a month | Stage | Price per weekly dose |
|---|---|---|---|
| 0.25 mg | To be confirmed | Starter dose, weeks 1 to 4 | To be confirmed |
| 0.5 mg | To be confirmed | Step 2 | To be confirmed |
| 1 mg | To be confirmed | Step 3 | To be confirmed |
| 1.7 mg | To be confirmed | Step 4 | To be confirmed |
| 2.4 mg | To be confirmed | Maintenance dose | To be confirmed |
| 7.2 mg | To be confirmed | Highest dose, given as three 2.4 mg doses each week | To be confirmed |
Missed a dose? Take your dose within 5 days. After 5 days, skip the dose and continue on your usual day. In the STEP UP trial, the 7.2 mg dose averaged 18.7% loss at 72 weeks, counting every participant. See the full Wegovy dose schedule.
What the trials found
STEP 1 tested semaglutide 2.4 mg in 1,961 adults for 68 weeks, alongside diet and activity support.
14.9%
average weight loss, counting every participant. The placebo group averaged 2.4%.
Other trials
- STEP UP (7.2 mg). 1,407 adults with BMI 30 or more without diabetes, 72 weeks. Mean weight change was -18.7% with 7.2 mg, -15.6% with 2.4 mg and -3.9% with placebo. 47.7%, 33.3% and 2.9% lost at least 20%. 31.2%, 15.3% and 0% lost at least 25% (UK SmPC table).
- SELECT (cardiovascular outcomes). 17,604 adults aged 45 or over with established cardiovascular disease and BMI 27 or more, without diabetes, mean follow-up 39.8 months. Cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.5% with semaglutide 2.4 mg and 8.0% with placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90). 16.6% versus 8.2% stopped because of adverse events.
- STEP 4 (withdrawal). After a 20-week run-in with 10.6% mean weight loss, 803 adults were randomised. From week 20 to 68 weight changed by -7.9% with continued semaglutide and +6.9% with placebo, a difference of 14.8 percentage points. People who stayed on semaglutide lost 17.4% in total from week 0 to 68 (SmPC).
- STEP 1 extension (after stopping). 327 participants were followed for a year after stopping. The semaglutide group had lost 17.3% by week 68, regained 11.6 percentage points by week 120 and kept a net loss of 5.6%.
Side effect rates in trials
| Effect | Rate | Dose |
|---|---|---|
| Nausea | 43.9% | 2.4 mg |
| Diarrhoea | 29.7% | 2.4 mg |
| Vomiting | 24.5% | 2.4 mg |
| Constipation | 24.2% | 2.4 mg |
| Stopped treatment because of a gastrointestinal event | 4.3% | 2.4 mg |
| Nausea | 38.9% | 7.2 mg |
| Diarrhoea | 24.2% | 7.2 mg |
| Vomiting | 22.1% | 7.2 mg |
Main trial: Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021, 384(11):989-1002. Individual results vary, and no result is promised.
Questions about support for Wegovy
Aero’s treatment prices and service inclusions will be confirmed before booking opens. Ask which prescribing, dispensing, delivery and follow-up costs are included in your quote.
- Before treatment begins, the prescribing clinician’s identity and professional registration must be clear. Aero’s named prescriber details will be published before booking opens.
- Agree a follow-up schedule with your prescriber, including how you report progress and side effects and who decides whether a dose should change.
Ask how to contact your clinical team
Questions about side effects, injecting or travel go to the pharmacy team who dispense your medicine. Clinical support hours and response times will be confirmed before the service launches.
What support includesSide effect help when you need help
You get practical steps for nausea, constipation and reflux, plus the warning signs needing urgent care.
Side effects and problemsFood, movement and sleep guidance
Nine guides cover protein, hydration, exercise and sleep, so you keep muscle while you lose weight.
Read the guides- Ask how maintenance care will be reviewed and priced. Aero’s longer-term service arrangements will be confirmed before booking opens.
How to use your Wegovy pen
- 1
Check
Wash your hands. Check the pen label and check the liquid is clear. Attach a new needle each time.
- 2
Choose a site
Stomach, thigh or upper arm. Rotate weekly. See the injection guide.
- 3
Inject
Dial your dose, press and hold, and count slowly to 6 before removing. The click confirms delivery.
- 4
Dispose
Needle into your sharps bin, cap the pen, back to the fridge.
Side effects and safety
Common and usually short-lived
Nausea, most often after a dose increase. Constipation or diarrhoea, reflux, tiredness and redness where you inject. Smaller meals, slower eating, less fat and plenty of water ease most of these.
Full side effects guideGet urgent help
Severe stomach pain reaching your back, pain under your right ribs with fever or yellowing skin, swelling of the face or throat, or vomiting so severe you keep no fluids down. Call 999 or go to A&E. For other concerns call 111.
Tell your prescriber about
Diabetes medicines (insulin or gliclazide need GP coordination), planned surgery with sedation, diabetic retinopathy, past gallbladder or pancreas problems, and any pregnancy plans.
Report any suspected side effect through the MHRA Yellow Card scheme. Read the patient leaflet in your pack before your first dose.
Safety information for all four medicinesWhen to get urgent help
Who can start Wegovy
Your prescriber makes the final decision after your health check.
Usually suitable
- Aged 18 to 75
- BMI of 30 or above
- BMI of 27 or above with a weight-related condition, such as high blood pressure
- Lower BMI thresholds can apply for some ethnic backgrounds
Not suitable
- Pregnant, breastfeeding or trying to conceive
- History of pancreatitis
- Personal or family history of medullary thyroid cancer or MEN2
- Type 1 diabetes, or a current eating disorder
Wegovy key facts
The main points from the UK product information and the main trial, in one table.
| Detail | Information |
|---|---|
| Active ingredient | Semaglutide |
| Medicine type | GLP-1 receptor agonist |
| Made by | Novo Nordisk |
| Form | Solution for subcutaneous injection in a pre-filled multi-dose FlexTouch pen |
| How often | Once weekly |
| Dose range | 0.25 mg to 7.2 mg |
| Dose steps | 6 doses, at least 4 weeks each |
| Highest dose | 7.2 mg once weekly |
| Main trial | STEP 1, 1,961 people, 68 weeks |
| Average loss in the main trial | 14.9% on 2.4 mg, against 2.4% on placebo |
| Storage | Fridge, 2 to 8°C before first use. 6 weeks below 30°C once in use |
| Missed dose | Take within 5 days, then skip |
| The contraceptive pill | No clinically relevant effect reported |
| Stop before a planned pregnancy | At least 2 months |
| Legal status | Prescription only medicine |
| On the NHS | Through specialist weight management services only |
| Price at Aero Clinic | To be confirmed |
Wegovy questions
How much does Wegovy cost a month?
Aero’s treatment prices are not yet confirmed. Before paying, ask for the total price, pack quantity, prescribing fees, dispensing and delivery charges, and follow-up costs. Use your provider’s written quote in the cost planner.
How long does one pen last?
A Wegovy FlexTouch pen contains four doses of its labelled strength. Follow the schedule and storage limits for your prescribed presentation. Check the patient leaflet and ask your pharmacist how much medicine each supplied pack covers.
Does Wegovy affect the contraceptive pill?
Semaglutide is not expected to reduce oral contraceptive effectiveness directly. Vomiting or severe diarrhoea can still affect pill absorption, so follow your contraceptive leaflet’s advice. Discuss contraception and pregnancy planning with your prescriber before starting or changing treatment.
What if I stop losing weight on Wegovy?
Discuss a plateau with your prescriber before changing your dose. A review can consider progress, side effects, eating patterns, activity and treatment goals. Our plateau guide helps organise those questions without assuming that a dose increase is needed.
Can I switch from Mounjaro to Wegovy?
A prescriber must assess and plan any switch between these medicines. There is no simple milligram-for-milligram conversion. Read our switching guide, then ask your clinician to confirm the timing, starting dose and follow-up arrangements for you.
Is there a tablet version?
Yes, Wegovy tablets received UK authorisation in June 2026. They contain semaglutide but have different dosing and administration instructions from injections. See the MHRA announcement; authorisation does not confirm Aero’s supply arrangements, prices or your suitability.
Wegovy guides
Other plans
Clinical governance
Awaiting clinical provider details
The dispensing pharmacy, GPhC registration number and Superintendent Pharmacist will be named here once confirmed. A UK prescriber reviews every order before any medicine is supplied.
Page information
- Summary
- Information about Wegovy (semaglutide), including weekly injection routines, dosing information, evidence, side effects and clinical assessment.
- Publisher
- Aero Clinic, operated by AERO HEALTHCARE LTD.
- Editorial update
- Clinical review
- Pending. An editorial update is not a clinical sign-off.
Cite as: Wegovy weight loss injection, Aero Clinic (https://www.cagri.co.uk), AERO HEALTHCARE LTD. https://www.cagri.co.uk/wegovy. Editorial update: 4 November 2026. Clinical review pending.